1School of Life and Environmental Sciences, University of Sydney, Sydney, Australia.
2The ithree Institute, University of Technology Sydney, Ultimo, NSW, Australia.
Microb Genom. 2019 Jan;5(1). doi: 10.1099/mgen.0.000242. Epub 2019 Jan 16.
Resistance to carbapenem and aminoglycoside antibiotics is a critical problem in Acinetobacter baumannii, particularly when genes conferring resistance are acquired by multiply or extensively resistant members of successful globally distributed clonal complexes, such as global clone 1 (GC1) . Here, we investigate the evolution of an expanding clade of lineage 1 of the GC1 complex via repeated acquisition of carbapenem- and aminoglycoside-resistance genes. Lineage 1 arose in the late 1970s and the Tn6168/OCL3 clade arose in the late 1990s from an ancestor that had already acquired resistance to third-generation cephalosporins and fluoroquinolones. Between 2000 and 2002, two distinct subclades have emerged, and they are distinguishable via the presence of an integrated phage genome in subclade 1 and AbaR4 (carrying the oxa23 carbapenem-resistance gene in Tn2006) at a specific chromosomal location in subclade 2. Part or all of the original resistance gene cluster in the chromosomally located AbaR3 has been lost from some isolates, but plasmids carrying alternate resistance genes have been gained. In one group in subclade 2, the chromosomally located AbGRI3, carrying the armA aminoglycoside-resistance gene, has been acquired from a GC2 isolate and incorporated via homologous recombination. ISAba1 entered the common ancestor of this clade as part of the cephalosporin-resistance transposon Tn6168 and has dispersed differently in each subclade. Members of subclade 1 share an ISAba1 in one specific position in the chromosome and in subclade 2 two different ISAba1 locations are shared. Further shared ISAba1 locations distinguish further divisions, potentially providing simple markers for epidemiological studies.
对碳青霉烯类和氨基糖苷类抗生素的耐药性是鲍曼不动杆菌的一个关键问题,尤其是当具有耐药性的基因被成功在全球分布的克隆复合体中获得时,例如全球克隆 1 (GC1)。在这里,我们通过反复获得碳青霉烯类和氨基糖苷类抗生素耐药基因来研究 GC1 复合体 1 谱系不断扩大的分支的进化。1 谱系起源于 20 世纪 70 年代末,而 Tn6168/OCL3 分支则起源于 20 世纪 90 年代末,其祖先已经对第三代头孢菌素和氟喹诺酮类药物产生了耐药性。在 2000 年至 2002 年间,出现了两个不同的亚分支,它们可以通过亚分支 1 中存在整合噬菌体基因组和亚分支 2 中特定染色体位置上的 AbaR4(携带 Tn2006 中的 oxa23 碳青霉烯类耐药基因)来区分。一些分离株中丢失了部分或全部原始耐药基因簇,但获得了携带替代耐药基因的质粒。在亚分支 2 中的一个群体中,携带 armA 氨基糖苷类耐药基因的染色体定位的 AbGRI3 已经从 GC2 分离株中获得,并通过同源重组整合。ISAba1 作为头孢菌素耐药转座子 Tn6168 的一部分进入该分支的共同祖先,并在每个亚分支中以不同的方式分散。亚分支 1 的成员在染色体的一个特定位置共享一个 ISAba1,而在亚分支 2 中则共享两个不同的 ISAba1 位置。进一步共享的 ISAba1 位置区分了进一步的分裂,可能为流行病学研究提供简单的标记。